HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata

Part of paid clinical trials in Tampa, Florida.

Sponsor
HCW Biologics
Study ID
NCT07049328
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Alopecia Areata(AA)

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • HCW9302, an IL-2 fusion protein — DRUG
    Injection

Study Details

This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)

Key Dates

Start date
Aug 16, 2025
Status verified
Aug 2025
Primary completion
Jul 16, 2026
Completion
Dec 15, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Study of HCW9302, an IL-2 fusion protein, for alopecia areata
    Single dose subcutaneous injection of HCW9302.

Primary Outcome Measure

Incidence of Treatment-Emergent Adverse Events (TEAEs) in Subjects Receiving HCW9302 Monotherapy [ Time Frame: 9 Weeks ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
James A. Haley Veterans' HospitalTampaFlorida33612
Adam Zoble, MS
[email protected]
813-972-2000
Thomas Beachkofsky, MD (PRINCIPAL_INVESTIGATOR)
The Ohio State University Wexner Medical CenterColumbusOhio43210
Alison Wandling, B.S. CCRC
[email protected]
614-685-0251
Benjamin Kaffenberger, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Tampa, FL

By research site
James A. Haley Veterans' Hospital· Tampa, FLThe Ohio State University Wexner Medical Center· Columbus, OH